Catalog No.S1465 Synonyms: BAY12-8039 HCl
Molecular Weight(MW): 437.89
Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent.
Purity & Quality Control
Choose Selective Topoisomerase Inhibitors
|Description||Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent.|
Moxiﬂoxacin exerts its effects by trapping a DNA drug enzyme complex and speciﬁcally inhibiting ATP-dependent enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. Moxiﬂoxacin shows in-vitro potency against M. tuberculosis H37Rv with MIC of 0.177 μg/mL. Moxiﬂoxacin has broad Grampositive and Gram-negative activity. Moxiﬂoxacin shows in vitro and clinical efﬁcacy against Staphylococcus aureus, Streptococcus pneumoniae, Str. pyogenes, Haemophilus inﬂuenzae, H. parainﬂuenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae and Mycoplasma pneumoniae. Moxiﬂoxacin has activity against mycobacteria in addition to M. tuberculosis; Moxiﬂoxacin is more active against M. kansasii than M. avium complex: speciﬁcally MIC90 for M. avium > M. intracellulare > M. kansasii at 4, 2 and 2 μg/mL, respectively. MIC90 for M. chelonae > M. fortuitum at 16 and 0.5 μg/mL, respectively. 
|In vivo||Moxiﬂoxacin combined with RIF/pyrazinamide (PZA) reduces treatment time by up to 2 months compared to regimens with isoniazid (INH)/RIF/PZA in a mouse model designed to mimic human disease. Similar results with a stable cure are reached after 4 months in mice treated twice weekly with RIF/Moxiﬂoxacin/PZA compared to cure in 6 months when daily treated with RIF/INH/PZA. 100 mg/kg Moxiﬂoxacin in mice gives activity comparable to INH; increased dose in mice to 400 mg/kg Moxiﬂoxacin daily results in spleen CFU counts lower than for INH 25 mg/kg although the differences are not statistically signiﬁcant. AUC/MIC ratio correlates best with in-vivo efﬁcacy for the ﬂuoroquinolones in a mouse model of tuberculosis. |
|In vitro||DMSO||87 mg/mL (198.68 mM)|
|Water||60 mg/mL (137.02 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02590523||Not yet recruiting||Intracameral Antibiotics|Cataract Surgery|Phacoemulsification|Endophthalmitis|Vancomycin|Moxifloxacin||Panhandle Eye Group LLP||January 2019||Phase 3|
|NCT03244072||Not yet recruiting||Endophthalmitis||Jason Ahee M.D.|Zion Therapeutics LLC||October 1 2018||Phase 2|Phase 3|
|NCT03696459||Recruiting||Healthy||Janssen Research & Development LLC||October 2 2018||Phase 1|
|NCT03609099||Not yet recruiting||Community-acquired Pneumonia||David Garcia Cinca|Fundacion Clinic per a la Recerca Biomédica|Miquel Ferrer - Investigator Coordinator|Hospital Clinic of Barcelona||September 15 2018||Phase 4|
|NCT03656952||Recruiting||Healthy||Pfizer||September 5 2018||Phase 1|
|NCT03657446||Recruiting||Healthy Subjects||Idorsia Pharmaceuticals Ltd.||September 18 2018||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.